|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we show that inhibition of HDAC6 synergizes with anti-PD-L1 immune checkpoint blockade in ARID1A-inactivated ovarian cancer.
|
31311810 |
2019 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Fukumoto and colleagues present a promising example of this approach for the treatment of ovarian cancer with inactivating ARID1A mutations using a combination of the checkpoint and histone deacetylase inhibitors.<i>See related article by Fukumoto et al., p. 5482</i>.
|
31676676 |
2019 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decreased gene and protein expression levels of ARID1A are related to the occurrence and development of endometriosis-associated ovarian cancer, especially OCCC.
|
29135119 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, ABT263 synergizes with an EZH2 inhibitor in vivo in ARID1A-inactivated ovarian tumor mouse models.
|
30297712 |
2018 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although EZH2 enzymatic inhibitors have shown antitumor effects in EZH2-mutated lymphoma and ARID1A-mutated ovarian cancer, many cancers do not respond because EZH2 can promote cancer independently of its histone methyltransferase activity.
|
29669287 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
|
29590609 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our results illustrated that ARID1A loss in ovarian cancer leads to MDR through upregulation of MRP2, providing an opportunity to overcome the ARID1A loss induced chemoresistance of ovarian cancer by targeting MRP2.
|
29660381 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors.
|
29736026 |
2018 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A key HDAC6 dependency of ARID1A-mutated ovarian cancer.
|
28752851 |
2017 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We also found that an activating (E545K) Pik3ca mutation, unlike Pten inactivation or Pik3ca H1047R mutation, cannot cooperate with Arid1a loss to promote ovarian cancer development in the mouse.
|
26279473 |
2016 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It has also been suggested that ARID1A mutation occurs at the early stage of canceration from endometriosis to endometriosis‑associated carcinoma in ovarian cancer and also from atypical endometrial hyperplasia to endometrioid adenocarcinoma in endometrial cancer.
|
26572704 |
2016 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Importantly, EZH2 inhibition caused regression of ARID1A-mutated ovarian tumors in vivo.
|
25686104 |
2015 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
ARID1A has been identified as a novel tumor suppressor gene in ovarian cancer and subsequently in various other tumor types.
|
24382590 |
2014 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms.
|
23232571 |
2013 |